{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dmards/management/leflunomide/","result":{"pageContext":{"chapter":{"id":"b87df30d-4917-58a4-84b5-2db454410a88","slug":"leflunomide","fullItemName":"Scenario: Leflunomide","depth":2,"htmlHeader":"<!-- begin field 8484cddf-063a-45d6-a62b-eaf1826848cc --><h2>Scenario: Leflunomide</h2><!-- end field 8484cddf-063a-45d6-a62b-eaf1826848cc -->","summary":"Covers the monitoring of leflunomide in adults in primary care.","htmlStringContent":"<!-- begin item ca4040e9-914c-4126-a5a2-da89df67ee11 --><!-- begin field dbe2edea-7cd2-4ffa-9902-acbc015c27a7 --><p>From age 18 years onwards.</p><!-- end field dbe2edea-7cd2-4ffa-9902-acbc015c27a7 --><!-- end item ca4040e9-914c-4126-a5a2-da89df67ee11 -->","topic":{"id":"493980c0-c660-5bda-b643-f98644c1eff8","topicId":"caed8aa7-f8ba-4a46-9441-92701c2ad78a","topicName":"DMARDs","slug":"dmards","lastRevised":"Last revised in April 2020","chapters":[{"id":"d587cd65-a186-50e3-a192-8d3f3b5c074b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e4b02852-ea41-536a-8ec9-462ecfc95b24","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"189d2086-77a0-57a3-84ed-6f44f1e56879","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ff583a6c-57af-5ded-8488-19039e0cd272","slug":"changes","fullItemName":"Changes"},{"id":"d65ec114-ec65-504e-a69b-b4fef29f3ca6","slug":"update","fullItemName":"Update"}]},{"id":"c02019ed-342b-5aa7-a645-a8c979fa0d56","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"0ee8d208-7733-5a7d-928a-41e080d05756","slug":"goals","fullItemName":"Goals"},{"id":"2206fe89-030d-5fec-adf5-ee4a379ff3a0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca18e3ee-b448-5d95-b060-d5ab2e909dd2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ce5c5664-0c85-52e9-b3d1-835fa7e52c8f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ac9bf99d-b5d4-5d63-8e5c-bb174916417e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2c23a774-3e76-52d5-8316-b8cbe2060151","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"33f76ef2-b579-5b80-985a-587d2f7cbb17","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"13df5021-0440-5dfe-b200-6910e116b50b","slug":"indications","fullItemName":"Indications"}]},{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","fullItemName":"Management","slug":"management","subChapters":[{"id":"a22ece65-e42d-59b8-82a9-4633e64a7441","slug":"general-principles-of-managing-dmards","fullItemName":"Scenario: General principles of managing DMARDs"},{"id":"7428c7c0-3189-5d82-8d3c-61151fc43773","slug":"apremilast","fullItemName":"Scenario: Apremilast"},{"id":"c241c22b-6dd4-5334-b240-a532f0f78fd7","slug":"azathioprine","fullItemName":"Scenario: Azathioprine"},{"id":"cff5fc6d-3554-5bf8-832a-c8a089699b6f","slug":"baricitinib","fullItemName":"Scenario: Baricitinib"},{"id":"fc4f9786-0db2-5fcd-a2ca-589807093e6a","slug":"biologics","fullItemName":"Scenario: Biologics"},{"id":"a8c361a4-0693-5e57-a935-24a8383a76ba","slug":"ciclosporin","fullItemName":"Scenario: Ciclosporin"},{"id":"92b93974-10b7-5147-b0cb-e21d187093e4","slug":"cyclophosphamide","fullItemName":"Scenario: Cyclophosphamide"},{"id":"928496d4-4642-55d5-98fe-86bd350c2913","slug":"gold-intramuscular","fullItemName":"Scenario: Gold - intramuscular"},{"id":"bed27174-d641-5a3b-958e-fdb3f1b0c33f","slug":"hydroxychloroquine","fullItemName":"Scenario: Hydroxychloroquine"},{"id":"b87df30d-4917-58a4-84b5-2db454410a88","slug":"leflunomide","fullItemName":"Scenario: Leflunomide"},{"id":"29f64422-8646-5cd9-ab79-c6919331e041","slug":"methotrexate","fullItemName":"Scenario: Methotrexate"},{"id":"c4758020-9fa5-5122-9cd7-c871ebd54d73","slug":"mycophenolate-mofetil-mmf","fullItemName":"Scenario: Mycophenolate mofetil (MMF)"},{"id":"5870b3d5-8b5b-5029-86fa-0f688b740005","slug":"penicillamine","fullItemName":"Scenario: Penicillamine"},{"id":"7b2bca14-9fd5-55c7-9a3f-bb044a5c53cb","slug":"sulfasalazine","fullItemName":"Scenario: Sulfasalazine"},{"id":"4fddf07b-12b6-51d6-93db-59bb536a2db1","slug":"tacrolimus","fullItemName":"Scenario: Tacrolimus"},{"id":"1dcd6206-8d6f-548c-a253-fc19d5deb6e7","slug":"tofacitinib","fullItemName":"Scenario: Tofacitinib"},{"id":"6e4b7cba-f4a1-5221-9b40-b3adeaf750bc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"0fcf14f9-de6c-5f14-b7e2-222e952f6aa4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"5bcf1ebc-c823-5866-8643-bb3a12bd2e78","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"99f1248a-29fc-5534-8f2a-306820d31914","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"92a3e377-bfa8-5bcb-92d5-38bd17e970e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"bb2fda74-5193-58b7-9e0b-40e6129a4629","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"65080272-e93d-5ccb-a5f0-bcecaca6aae1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"44895091-401a-5a9b-b11f-a4e952ec6de2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"caffbaca-bd54-566b-921b-c2363a59a842","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"f919120c-d8c9-5fb7-b29a-fe422146fc29","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"9a97d1bd-247b-5ce6-ac0e-3f8bf4f24745","slug":"leflunomide-monitoring-requirements","fullItemName":"Leflunomide monitoring requirements","depth":3,"htmlHeader":"<!-- begin field e7e3d72d-08cd-41dc-8d17-6df8abb1c513 --><h3>What monitoring is required for leflunomide?</h3><!-- end field e7e3d72d-08cd-41dc-8d17-6df8abb1c513 -->","summary":null,"htmlStringContent":"<!-- begin item c31d9fd3-25be-466c-beec-eac4be29e9b4 --><!-- begin field 39669be2-05b3-4280-afbc-469ce7927062 --><ul><li>For information on when to refer people on leflunomide, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/dmards/management/general-principles-of-managing-dmards/#when-to-refer\">when to refer</a>.<ul><li>Simple dose reduction is unlikely to produce a rapid diminution of adverse effects as the half-life of leflunomide is usually 2 weeks (range 1–4 weeks). If a rapid response is required, <a class=\"topic-reference internal-reference\" href=\"/topics/dmards/management/leflunomide/#leflunomide-washout\">washout</a> may be considered by the specialist team in secondary care.</li></ul></li></ul><p><strong>Table 7.</strong> Primary care monitoring requirements for people on leflunomide.</p><table><thead><tr><th colspan=\"1\">Monitoring</th><th colspan=\"1\">Frequency</th></tr></thead><tbody><tr><td colspan=\"1\">Full Blood Count (FBC)</td><td colspan=\"1\" rowspan=\"5\"><ul><li>Every 2 weeks until dose is stable for 6 weeks. </li><li>Then monthly for 3 months<sup>*</sup>.</li><li>Thereafter, at least every 12 weeks.<ul><li>More frequent monitoring is appropriate in patients at higher risk of toxicity</li></ul></li><li><strong>Dose increases:</strong> Every 2 weeks until dose is stable for 6 weeks, then revert to previous schedule.</li></ul></td></tr><tr><td colspan=\"1\">Creatinine/calculated GFR</td></tr><tr><td colspan=\"1\">Liver Function Tests (LFTs): ALT and/or AST and albumin</td></tr><tr><td colspan=\"1\">Blood pressure</td></tr><tr><td colspan=\"1\">Weight</td></tr><tr><td colspan=\"2\">AST, aspartate transaminase; ALT, alanine aminotransferase; GFR, glomerular filtration rate.</td></tr><tr><td colspan=\"2\">*If leflunomide is combined with methotrexate, continue monthly monitoring until stable for 12 months, then consider reduced frequency monitoring on an individual basis.</td></tr><tr><td colspan=\"2\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BSR, 2017</a>]</td></tr></tbody></table><!-- end field 39669be2-05b3-4280-afbc-469ce7927062 --><!-- end item c31d9fd3-25be-466c-beec-eac4be29e9b4 -->","subChapters":[{"id":"75d6c0b8-34bb-57b3-82a9-7339241b298e","slug":"basis-for-recommendation-981","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4547d4d8-0a2a-4189-8b25-b81ca9432d63 --><h4>Basis for recommendation</h4><!-- end field 4547d4d8-0a2a-4189-8b25-b81ca9432d63 -->","summary":null,"htmlStringContent":"<!-- begin item 98177ef4-3d29-477f-a798-9f02f4445e25 --><!-- begin field ff20f5e3-99b6-436f-9689-299999849e7a --><p>These recommendations are based on the British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) <em>BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BSR, 2017</a>], shared care guidelines for disease modifying antirheumatic drugs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">Gough, 2014</a>], and the manufacturer's Summary of Product Characteristics for leflunomide [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017p</a>].</p><!-- end field ff20f5e3-99b6-436f-9689-299999849e7a --><!-- end item 98177ef4-3d29-477f-a798-9f02f4445e25 -->","subChapters":[]}]},{"id":"eb8a03c3-4e54-5491-b47c-838113efd0bc","slug":"leflunomide-washout","fullItemName":"Leflunomide washout","depth":3,"htmlHeader":"<!-- begin field 9bd57e78-28fd-4257-8635-e533d06c56cf --><h3>How do I 'wash-out' leflunomide?</h3><!-- end field 9bd57e78-28fd-4257-8635-e533d06c56cf -->","summary":null,"htmlStringContent":"<!-- begin item f226a271-3012-490f-9a3d-8f16d6eebe07 --><!-- begin field a684554d-05fc-4937-a660-be327019e581 --><ul><li><strong>Washout procedure:</strong><ul><li>After stopping treatment with leflunomide:<ul><li>Administer colestyramine 8 g three times daily for 11 days.</li><li>Alternatively, give activated powdered charcoal 50 g four times daily for 11 days.</li></ul></li></ul></li><li>The decision to inititate washout will be managed by the specialist team in secondary care.</li></ul><!-- end field a684554d-05fc-4937-a660-be327019e581 --><!-- end item f226a271-3012-490f-9a3d-8f16d6eebe07 -->","subChapters":[{"id":"3e51ea3d-1fec-5003-978e-d669cd5cf9ba","slug":"basis-for-recommendation-875","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c83acbc9-2d05-40d5-88f9-0b85d3e0556f --><h4>Basis for recommendation</h4><!-- end field c83acbc9-2d05-40d5-88f9-0b85d3e0556f -->","summary":null,"htmlStringContent":"<!-- begin item 875348e3-b1a4-44f5-b2ae-79b86b61bacd --><!-- begin field 6df1d932-a5b9-4552-b80a-c61582dc779f --><p>These recommendations are based on the British Society for Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) <em>BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">BSR, 2017</a>], and the manufacturer's Summary of Product Characteristics for leflunomide [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dmards/references/\">ABPI, 2017p</a>].</p><!-- end field 6df1d932-a5b9-4552-b80a-c61582dc779f --><!-- end item 875348e3-b1a4-44f5-b2ae-79b86b61bacd -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}